Online citations, reference lists, and bibliographies.
← Back to Search

Biomarkers In Malignant Mesothelioma: Diagnostic And Prognostic Role Of Soluble Mesothelin-Related Peptide

N. Dipalma, V. Luisi, F. di Serio, A. Fontana, P. Maggiolini, Brunella Licchelli, E. Mera, L. Bisceglia, I. Galise, M. Loizzi, Maria Annunziata Pizzigallo, R. Molinini, L. Vimercati
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). The aim of this study was to evaluate the role of SMRP in clinic management of MM. We assayed the SMRP concentrations in 354 subjects: 109 healthy volunteers with no history of exposure to asbestos, 26 patients with previous occupational asbestos exposure but who were free from pleural or parenchymal disease, 48 patients with asbestosis, 110 patients with pleural plaques, 25 patients with lung cancer, and 36 patients with MM. We also tested SMRP titers in 2 patients with MM at 5 different times of the disease, to evaluate the trend of the biomarker in the course of therapy. Our data confirm previous experiences with the use of SMRP as a diagnostic marker of MM. Low SMRP levels at diagnosis seem to have a positive prognostic significance.
This paper references
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Surviving the asbestos epidemic
N Shah (2001)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.5301/JBM.2011.8332
Two Novel Polymorphisms in 5' Flanking Region of the Mesothelin Gene are Associated with Soluble Mesothelin-Related Peptide (SMRP) Levels
A. Cristaudo (2011)
Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali. seconda edizione
It Istituto Superiore di Sanit (2004)
10.1111/J.1445-5994.1999.TB00777.X
Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Y. Lee (1999)
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
Medical surveillance of workers previously exposed to asbestos.
A. Cristaudo (2006)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1515/CCLM.2007.112
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
F. di Serio (2007)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1164/rccm.200310-1436st
Diagnosis and initial management of nonmalignant diseases related to asbestos.
D. Smith (2005)
10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma
A. Thylén (2001)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1148/RADIOLOGY.143.1.7063747
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
J. Hanley (1982)



This paper is referenced by
10.2174/1874944502013010075
Sitting Occupations and Physical Intensity of Work as Predictors of Mortality: A Retrospective Study of a Population of Workers in Southern Italy
A. Caputi (2020)
10.3390/ijerph17072321
Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel
L. Vimercati (2020)
10.1016/j.cllc.2020.05.020
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
Juuso Paajanen (2020)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.3390/ENVIRONMENTS6070076
Epidemiology of Mesothelioma
D. Cavone (2019)
10.18632/oncotarget.17436
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
Long Tian (2017)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.2147/CMAR.S201269
High systemic immune–inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma
M. Ma (2019)
10.2174/1874944502013010069
Occupational Exposure to Noise and Age-related Hearing Loss in an Elderly Population of Southern Italy
L. Maria (2020)
10.1007/978-1-4471-2825-0_19
Malignant Mesothelioma: Molecular Markers
E. Kettunen (2014)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.1016/j.taap.2012.02.006
Acute phase response, inflammation and metabolic syndrome biomarkers of Libby asbestos exposure.
J. Shannahan (2012)
10.3390/ijerph17082636
Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory
L. Vimercati (2020)
10.1080/15287394.2014.899171
Early and Delayed Effects of Naturally Occurring Asbestos on Serum Biomarkers of Inflammation and Metabolism
U. Kodavanti (2014)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
10.3389/fgene.2020.00975
Variation rs2235503 C > A Within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide
Roberto Silvestri (2020)
10.15167/2421-4248/jpmh2019.60.4.1330
Health impact of exposure to asbestos in polluted area of Southern Italy
L. Vimercati (2019)
10.1016/j.jtho.2016.02.006
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
H. Pass (2016)
10.1186/s12940-019-0512-4
Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: a systematic review and the experience of the Apulia (southern Italy) mesothelioma register
L. Vimercati (2019)
10.1186/s13104-019-4675-4
Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy
L. Vimercati (2019)
Semantic Scholar Logo Some data provided by SemanticScholar